Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse

Yasuhiro Nishino1, Ian G Webb, Sean M Davidson

  • 1King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, UK.

Circulation Research
|June 28, 2008
PubMed

Insights

Glycogen synthase kinase-3 (GSK-3) inactivation is not the primary mechanism behind heart protection from preconditioning or postconditioning. Novel genetic mouse models show that GSK-3 inhibition is unlikely to be the key determinant of cardioprotective signaling.

Area of Science:

  • Cardiovascular Research
  • Molecular Cardiology
  • Cellular Signaling

Background:

  • Glycogen synthase kinase-3beta (GSK-3beta) inactivation is hypothesized to integrate cardioprotective pathways.
  • GSK-3 inactivation is thought to prevent mitochondrial permeability transition pore (mPTP) opening.

Purpose of the Study:

  • To investigate the role of GSK-3 in mediating cardioprotection using a novel genetic mouse model.
  • To determine if GSK-3 inhibition is essential for preconditioning and postconditioning-induced myocardial protection.

Main Methods:

  • Utilized a targeted mouse line with mutated GSK-3beta (Ser9) and GSK-3alpha (Ser21) to prevent inactivation.
  • Applied preconditioning and postconditioning protocols to isolated perfused mouse hearts.
  • Administered pharmacological GSK-3 inhibitors and cyclosporin A (a direct mPTP inhibitor).
  • Assessed infarct size and mPTP opening in wild-type and GSK-3 mutant hearts.

Main Results:

  • Both preconditioning and postconditioning reduced infarct size in wild-type and GSK-3 mutant mouse hearts.
  • Pharmacological GSK-3 inhibition did not replicate conditioning-induced protection.
  • Cyclosporin A and insulin effectively inhibited mPTP opening in GSK-3 mutant cardiac myocytes.

Conclusions:

  • GSK-3 inactivation is unlikely to be the critical mediator of cardioprotection induced by preconditioning or postconditioning in mice.
  • Mitochondrial permeability transition pore inhibition remains a key target for cardioprotection, independent of GSK-3 activity.

Related Concept Videos